QUESTCOR RETIRES REMAINING DEBT OF $2.1 MILLION

Questcor Pharmaceuticals, Inc., a specialty pharmaceutical company that develops and commercializes novel therapeutics for the treatment of neurological disorders, today announced that it has retired $2.1 million in debt to Defiante Farmaceutica, Lda. "The elimination of our remaining debt reflects the efforts we have made to improve our capital structure as we transform Questcor into a true CNS-focused specialty pharmaceutical company," stated James L. Fares, President and CEO of Questcor.

Business Wire (http://home.businesswire.com/portal/site/google/index.jsp?ndmViewId=news_view&newsId=20051017006017&newsLang=en)